Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Monopar Therapeutics Inc.NASDAQ: MNPR
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $4 (cash outflow) rose 0.0% year over year, ahead of the -50.0% change in trailing-twelve-month capital expenditures.
Context
- Capital expenditures increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of -50.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 1 | — |
Capital Expenditures vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.0% is the 5th highest of 10, against a peer median of -55.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $9.67M USD | +36.9% | +239.3% | — | |
| LTM Jun 2026 | $2.47M USD | -62.7% | -58.3% | 2.4% | |
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
| LTM Sep 2026 | $858.9K USD | -55.9% | -51.2% | 0.3% | |
| LTM Jun 2026 | $584K USD | — | -34.3% | 1.7% | |
| LTM Mar 2026 | $202K USD | -43.7% | -47.0% | — | |
| FY2025 | €134.47K EUR | -65.6% | -50.7% | 4.8% | |
| LTM Mar 2026 | $106.68K USD | -94.2% | -50.1% | 0.2% | |
| LTM Mar 2026 | $89K USD | +43.5% | -51.0% | — | |
| LTM Mar 2026 | $57.04K USD | -90.5% | -27.3% | 0.1% | |
| LTM Mar 2026 | $3 USD | -50.0% | — | — | |
| Peer median (excluding MNPR) | — | -55.9% | -48.6% | 1.1% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.47M | 1.64M | 1.9M | 1.14M | 4.84M |
| Change in Working Capital | 317.77K | 1.65M | (1.35M) | 3.49M | (2.61M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 403.97K | 1.48M | (1.33M) | 506.79K | 388.22K |
| Other Working Capital | (86.2K) | 167.52K | (20.41K) | 2.98M | (2.99M) |
| Other Non-Cash Items | 0 | 0 | 0 | 4.55M | (716.46K) |
| Operating Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
| Capital Expenditures | 1 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (4.92M) | (7.88M) | (15.32M) | (87.15M) |
| Sales of Investments | 0 | 0 | 12.81M | 985.73K | 23.7M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.92M) | 4.93M | (14.34M) | (63.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.93M | 109.34K | 2.07M | 59.4M | 127.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (35M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45.78K) | (76.46K) | (46.97K) | (104.14K) | (1.13M) |
| Financing Cash Flow | 10.88M | 32.87K | 2.03M | 59.29M | 91.57M |
| Effect of Forex Changes | 4.62K | (3.48K) | (16.8K) | 494 | 97.27K |
| Net Change in Cash | 3.57M | (12.12M) | (920.11K) | 38.55M | 16.02M |
| Free Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.